Commercially available lipid formulations of amphotericin B (Abelcet, Amphotec, and AmBisome) represent a significant advance in drug delivery technology. Differences in biochemical, pharmacokinetic, and pharmacodynamic properties among the lipid products have been shown in in vitro and in vivo models. Clinical experience with these products has been primarily in patients either refractory to or intolerant of conventional amphotericin B deoxycholate (AmBd). None of the lipid-based products demonstrates superior efficacy when prospectively compared with AmBd in the treatment of documented infections. When used for the empirical treatment of febrile neutropenia, AmBisome significantly reduced the incidence of proven emergent fungal infections but did not improve shortterm survival rates, in comparison with AmBd. Acute infusion-related adverse events vary, whereas nephrotoxicity is reduced with all three lipid formulations. Until superior efficacy is clearly shown (for documented infections) or pharmacoeconomic analyses document the value of these drugs, use of such expensive agents should be highly restricted to those who are intolerant of or refractory to AmBd.
Despite the availability of newer, less toxic azoles, amphothird product, AmBisome (L-AmB; NeXstar Pharmaceuticals/ Fujisawa, San Dimas, CA), long commercially available outtericin B (AmB) remains the agent of choice for treatment of many serious systemic fungal infections. The recent developside of the United States, received FDA approval in August 1997. ment of resistance to azoles and the increased prevalence of fungal infections have reemphasized the value of AmB. HowThis article will provide a basic understanding of the use of phospholipid vesicles as a drug delivery system. In addition, ever, the usefulness of the conventional AmB deoxycholate (AmBd) formulation is limited by its well-known dose-limiting the biochemical, pharmacokinetic, and pharmacodynamic differences among the lipid-formulated AmB products also will nephrotoxicity.
For the past decade, investigators have evaluated the use of be discussed. Finally, a critical evaluation of the clinical efficacy and toxicity of these products, based on the Englishphospholipid vesicles known as liposomes as a target drug delivery system for AmB, in an attempt to attenuate its nephrolanguage literature (including abstracts), will be performed to clarify the potential role of each product. toxicity and increase its therapeutic potential. Lopez-Berestein et al. created the first liposomal formulation of AmB experimented with in humans [1] . Their experience led to further Liposomes as Drug Delivery Systems development of the lipid formulations of AmB by the pharmaceutical industry. In December 1995, amphotericin B lipid comLiposomes are biodegradable vesicles that consist of an plex, or ABLC (Abelcet; The Liposome Co., Princeton, NJ), aqueous environment surrounded by phospholipid bilayers. The became the first lipid-formulated AmB product to receive apfirst description of liposomes was made over 30 years ago by proval by the U.S. Food and Drug Administration (FDA) for Alec Bangham in Cambridge, England, who noted the spontause in the United States. Subsequently, another lipid-formuneous formation of microscopic closed vesicles when high conlated AmB product, amphotericin B colloidal dispersion, or centrations of phospholipids were dispersed in water [2] . In ABCD (Amphotec; Sequus Pharmaceuticals, Menlo Park, CA), the ensuing years, researchers using various methods were able received FDA approval in December 1996. More recently, a to produce liposomes with different biochemical properties by altering characteristics such as size, electrical charge, permeability, and lipid composition of the vesicles. For the past 20 years, the practical application of liposomes NOTE. ABCD Å amphotericin B colloidal dispersion; ABLC Å amphotericin B lipid complex; AmBd Å amphotericin B deoxycholate; CHOL Å cholesterol; DMPC Å dimirystoylphosphatidylcholine; DMPG Å dimirystoylphosphatidylglycerol; DSPG Å distearoylphosphatidylglycerol; HPC Å hydrogenated phosphatidylcholine; L-AmB Å AmBisome.
* Average concentrations of AmB in tissue obtained at autopsy from six patients who received cumulative AmB doses ranging from 206 mg to 2,688 mg.
† Tissue concentrations at autopsy in one heart transplant patient who received three doses of ABLC (5.3 mg/[kgrd]).
‡ Average tissue concentrations at autopsy in three patients who received cumulative doses ranging from 820 mg to 3,428 mg of AmBisome.
§ Figures are available only for AmBd and L-AmB and were calculated on the basis of total drug per organ (mg), divided by total dose received (mg).
for liposomal incorporation. Theoretically, entrapment of AmB some is the only commercially produced lipid formulation that contains liposomal structures. into liposomes would increase its therapeutic index through selective transfer of AmB to the target fungal cell, with reduced uptake into human cells.
The first liposomal AmB formulation evaluated in humans In Vivo Disposition consisted of multilamellar vesicles made up of a mixture of two phospholipids, dimyristoylphosphatidylcholine (DMPC)
The pharmacokinetics and tissue distribution of the drugand dimyristoylphosphatidylglycerol (DMPG), in a 7:3 molar laden liposomes are strongly affected by their physicochemical ratio containing 5% -10% mole ratio of amphotericin to lipid.
properties, such as vesicle size, bilayer rigidity, and surface The initial clinical experience with liposomal AmB involved electrical charge [9, 10] . Larger liposome vesicles clear more neutropenic cancer patients with progressive fungal infections rapidly from the bloodstream than smaller ones, while posirefractory to treatment with AmBd [5, 6] . Although uncontively charged and neutral liposomes circulate longer than those trolled, treatment results suggested that invasive refractory funof a similar size that are negatively charged. The surface electrigal disease may respond to liposomal AmB. In addition, liposocal charge differs by the type of phospholipid (i.e., phosphatimal AmB appeared to be less nephrotoxic than AmBd. dylcholine vs. phosphatidylglycerol). Moreover, the addition This initial clinical experience led to the development of of cholesterol to the phospholipid bilayers enhances liposomal similar products over the past 10 years. Of the three lipidstability, resulting in a decreased rate of vesicle clearance from formulated AmB products that are commercially produced tocirculation and a longer biological half-life. day, ABLC is most closely related to the original formulation.
Although plasma levels achieved with all three products ABLC consists primarily of the nonliposomal structures of the differ from one another, the clinical significance of such a lipid bilayers, called ribbons, which were responsible for the difference is unknown [10, 11] ; the extent of tissue distribution observed reduction in toxicity [7, 8] . The concentration of AmB may be an important determinant of treatment outcome. On in ABLC is 33 mol%, vs. 2% -7% by weight for the original the basis of autopsy data obtained from eight patients who formulation. The other two commercial lipid-based products received the conventional AmBd formulation, tissue drug condiffer from ABLC, not only in vesicular structure but also in centrations were found to be highest in the liver and spleen, phospholipid composition and AmB content ( Both ABLC and L-AmB distribute minimally to the kidneys, ioidomycosis [24] . However, ABCD was equally effective and less toxic than conventional AmBd for cryptococcosis [25] . On heart, and lungs and concentrate primarily in the spleen and liver, where the reticuloendothelial system phagocytic cells the other hand, L-AmB treatment resulted in longer survival when given at doses equal to those of AmBd for invasive reside [13, 14] . The low concentrations of drug found in kidneys correlate with the clinical observation of reduced nephroaspergillosis, but the greatest rate of reduction of pulmonary hemorrhage was at a dosage of 5 mg/[kgrd] [26] . toxicity of ABLC and L-AmB. No data detailing the distribution pattern of ABCD in humans are available at present. One
Only data from one study has presented a direct comparison of the in vivo activities of all three lipid-based products against factor complicating interpretation of data concerning serum and tissue concentrations is the inability to differentiate beone another and against AmBd in a murine model of cryptococcosis [27] . Treatment groups of 10 mice each received 1, 5, tween lipid-bound and free amphotericin; the bioavailability of AmB may be highly variable among the three preparations, 10, and 1 mg/kg of ABCD, ABLC, L-AmB, and AmBd, respectively. When treatment groups were compared at the 1-mg/kg owing to their biochemical differences [10] . Future studies are needed to evaluate the relationship between serum or tissue dosage levels, survival rates were better with all lipid-based products than with AmBd, in the following order: ABCD ú concentrations of AmB in lipid-formulated products and treatment outcomes.
L-AmB ú ABLC ú AmBd. Even though the authors noted that ABCD was equivalent to L-AmB and that both were superior to Following intravenous administration, uptake by the reticuloendothelial system accounts for the major disposition of lipo-ABLC in reducing fungal burden in the brain, none of the mice survived free of infection at the site. In summary, animal data somes [15, 16] . In addition, liposomes may be distributed to various tissues by association with circulating lipoproteins in suggest that the optimal AmB preparation and treatment dose depend on the specific pathogen. the bloodstream such as high-and low-density lipoproteins [16] . It is hypothesized that monocytes/macrophages in peripheral blood take up the drug-laden liposomes and transport them Clinical Experience to the site of inflammation or infection [17, 18] . In the setting of neutropenia, plasma lipoproteins may assume a major role To date, clinical experience with these products has primarily been in compassionate-use studies and small series of cases. in the transport mechanism [16] . Once the drug-laden liposomes or lipid complexes reach the site of action, it is specuAll English-language studies published (excluding case reports and abstracts) are summarized in table 2. Only patients with lated that free active drug is released through the action of phospholipases [7, 16, 19] .
documented systemic fungal infections are included. As yet, no comparative studies between lipid-based AmB products Some fungi produce extracellular phospholipases, as do activated mammalian cells, including phagocytic cells, vascular have been performed. Efficacy data available on the new products have concerned a wide range of systemic mycoses: candismooth-muscle cells, and capillary endothelial cells. These cells exist in a wide variety of tissues, including liver, spleen, diasis, aspergillosis, cryptococcosis, fusariosis, mucormycosis, and coccidioidomycosis. lung, and vascular smooth muscle under inflammatory conditions. It is possible that the amounts of AmB that are bioavailaBecause candidiasis and aspergillosis have been the most frequently treated infections, relative efficacy will be reviewed ble depend upon the infecting fungal organism, the presence of neutropenia, or extent of inflammation, potentially influencfor these indications. A comparison of the toxicity profiles for each product will emphasize acute infusion-related adverse ing the treatment dose required for optimal response. events (IRAEs) and nephrotoxicity. Other toxicities such as hypokalemia and anemia will not be discussed here, as they were inconsistently reported in the available literature.
Pharmacodynamic Comparison
Both the phospholipid:AmB ratio and the type of phosphoAmphotericin B Lipid Complex lipid appear to be important determinants of fungicidal activity and toxicity [20] . Differential activity has been documented ABLC was the first lipid-based formulation to receive FDA approval in United States. The original approved indication was between conventional AmBd and individual lipid-formulated product on a milligram-per-milligram basis in various animal limited to the treatment of aspergillosis in patients refractory to or intolerant of conventional AmBd. The indication has now models of fungal infection. ABLC was determined to be less active than AmBd in a murine model of invasive aspergillosis expanded to include all fungal infections. Clinical experience with ABLC primarily has been compasin immunocompromised animals; up to five times as much ABLC was required to achieve similar survival rates [21] . Efficacy -open-label use. Pooled data are available from serum creatinine level above 2.5 mg/dL. In most treated patients, hematologic malignancy was the primary underlying ú1,500 patients who received ABLC under the compassionate- (4) disorder. Of note, many were treated for ''presumed'' infecsented the efficacy and safety data for a total of 551 patients with documented invasive fungal infections, reported overall tions. Mean cumulative doses of up to 10,300 mg were used, with a mean daily dose of 5 mg/kg. Treatment duration ranged response rates of 70% (74 of 105) vs. 48% (82 of 170) (P Å .0004) for yeasts and filamentous fungi, respectively [55] . from 11 to 33 days.
In general, response to treatment with ABLC was greater The success of ABLC in patients whose AmBd therapy had previously failed was not stated. The overall mycologic eradifor candidiasis than for aspergillosis. One abstract, which pre-cation rate was between 52% and 75%, although analysis by therapy. Overall response rates were 65% with ABLC and 61% with AmBd. Comparable clinical responses were observed with organism was not possible because of inconsistent reporting.
Efficacy -comparative trials. Two prospective comsubgroup analysis: underlying condition, neutrophil count, infection type, pathogen, and central venous cathether status. In parative trials have been performed evaluating ABLC vs. AmBd in the treatment of cryptococcal meningitis in pageneral, patients with hematologic malignancy, neutropenia, candidemia, infections due to multiple Candida species, and tients with AIDS [29] and invasive candidiasis [52] , respectively. Data from the latter study presently are available in central venous catheters remaining in place tended to respond less favorably to treatment by either agent. For approximately abstract form.
In a randomized, open-label, ascending-dose study, ABLC half the evaluable patients, mycologic examination was performed to document eradication (88%, ABLC; 87%, AmBd). and AmBd were compared in the treatment of cryptococcal meningitis [29] . The primary study objective was to evaluate No significant differences in relapse or survival rates were observed at the 3-month follow-up. the safety and tolerance of ABLC, with efficacy as a secondary evaluation. A total of 55 patients were randomized into 4 treatToxicity. Both prospective comparative trials indicated that IRAEs associated with ABLC infusion occurred in one-third ment groups: 3 groups received an ascending dose of ABLC at 1.2, 2.5, and 5 mg/(kgrd) for 2 weeks, followed by 2.5, 5, to one-half of the treated patients, comparable to the rate with AmBd [29, 52] . In one retrospective analysis of pediatric cancer and 5 mg/kg thrice weekly for 4 weeks, respectively; the fourth group received AmBd at a dosage of 0.7 mg/(kgrd) for 2 patients, ABLC administration resulted in an incidence of IRAEs that was similar to that with AmBd, on the basis of weeks, followed by 1.2 mg/kg thrice weekly for 4 weeks.
Factors predictive of treatment failure and early death, such premedication requirements (87% vs. 80%) [56] .
Pooled data from emergency-use studies indicate that renal as visual abnormality, lethargy or obtundation, and a positive blood culture, were more prevalent in the ABLC groups. With function stabilized in a majority of patients; some even experienced improvement in renal function despite continuation of respect to treatment outcomes, no significant difference in response was noted between treatment groups. Patients in the therapy with ABLC [28 -30, 40 -56] . Significantly more patients receiving AmBd than those receiving ABLC had an elelower-dose ABLC groups (1.2 and 2.5 mg/[kgrd]) appeared to respond favorably to treatment; however, the small number vation in the serum creatinine level from baseline at weeks 2 and 3 in the treatment of cryptococcal meningitis [29] . Howof patients in each group (n Å 8, n Å 9) did not allow for meaningful interpretation of the efficacy data.
ever, baseline serum creatinine values were not stated for those who experienced a significant change following AmBd treatWhen results were compared between the ABLC 5 mg/(kgrd) group (n Å 21) and the AmBd 0.7 mg/(kgrd) group (n Å 17), ment. Similarly, the number of patients with reversible nephrotoxicity was not stated. comparable treatment successes were found both with intent-totreat analysis (38% vs. 41%) and subgroup analysis among paIn another comparative trial of invasive candidiasis, the incidence of nephrotoxicity was observed to be delayed and retients who had received at least 12 doses of the study drug (42% vs. 50%). Notably, a higher number of ABLC patients had duced in the ABLC group [52] . Doubling of baseline serum creatinine values occurred in 28% vs. 47% of patients receiving persistently positive CSF cultures at the end of treatment, despite resolution of symptoms (42% vs. 14%). The disproportionate ABLC and AmBd, respectively. Study withdrawal due to nephrotoxicity occurred in 19% of AmBd vs 8% of ABLC recipishare of negative predictive outcome factors present in the ABLC groups may have influenced the above results.
ents. However, criteria for withdrawal were not defined. In addition, the effect of concurrently administered nephrotoxic A second prospective, randomized, comparative trial evaluated ABLC vs. AmBd in 231 patients for the treatment of invasive agents in patients who developed nephrotoxicity was not stated. One recent retrospective analysis of patients with aspergillocandidiasis [52] . Invasive disease was defined as candidemia, acute disseminated candidiasis, or organ infection. Patients from sis suggested that ABLC reduced the need for dialysis secondary to AmB-induced nephrotoxicity and thus improved survival 27 centers were randomized to receive ABLC (5 mg/[kgrd]) or AmBd (0.6-1.0 mg/[kgrd]) in a 2:1 randomization scheme.
rates [54] . However, the findings of this study require confirmation in a prospective comparative trial. ABLC has been well Study groups were similar with respect to baseline characteristics, including age, underlying condition, and presence of neutropenia, tolerated with minimal toxicity in six patients who received unusually large cumulative doses over prolonged periods of as well as infection and pathogens. Hematologic malignancy and solid tumor were the major underlying disorders in both groups.
time (22.3 -73.6 g over 21 -121 weeks) [57] .
Other notable toxic effects include elevated serum bilirubin Candidemia was the major treatment indication in both groups (85%, ABLC; 83%, AmBd), and Candida albicans was the priand serum alkaline phosphatase levels. In a small retrospective analysis of pediatric patients with cancer, ABLC was withmary pathogen in half of the patients. The median treatment duration was 14 days in both groups.
drawn from four patients (27%) because of hyperbilirubinemia [56] . The serum bilirubin level as well as the alkaline phosphaEfficacy was evaluated only in those patients (124 ABLC and 70 AmBd recipients) who had positive baseline cultures, tase level were found to be significantly increased at the end of ABLC therapy in a large analysis of open-label multicenter had received at least 4 days of treatment with the study drug, and were given fewer than 4 days of other concurrent antifungal trials of patients receiving ABLC therapy for documented inva- A minority of the documented infections were coccidioidowere 22 days and 4,856 mg in that study [55] .
In addition, a recent abstract described severe hepatic cholemycosis, cryptococcosis, mucormycosis, and fusariosis. Treatment with ABCD resulted in a response rate (including comstasis prior to death in three transplantation patients who received ABLC in combination with cyclosporine. A temporal plete and partial responses) of 58% for candidiasis and 37% for aspergillosis, respectively. Mycologic eradication rates correlation between ABLC (5 mg/[kgrd]) administration and rise in serum bilirubin was observed [58] . The severity of were not determined in most studies. As expected, the treatment response with use of ABCD in documented systemic infections ABLC-associated hepatotoxicity reported here has not been corroborated by reports from other centers; however, close correlated with the presence of neutropenia (£500 neutrophils/ mm 3 ); 39% of those who were neutropenic vs. 64% of nonneumonitoring of patients receiving such a combination is imperative.
tropenic patients responded [31] . The daily treatment dose of ABCD was highly variable Summary -ABLC. ABLC appears to be as effective as AmBd in the treatment of invasive candidiasis and cryptococcal within and among studies, ranging from 0.5 mg/kg to 8 mg/kg. Although no dose-response relationship could be documeningitis in patients with AIDS. However, further comparative studies are warranted to confirm the efficacy results and mented in the phase I study, it is possible that different dosages are required to achieve optimal responses, depending upon the better define the optimal treatment dose. Comparative studies evaluating low-dose ABLC (2.5 mg/kg) vs. conventional pathogen (e.g., Candida vs. Aspergillus). Of note, the clinical response reported from one small study of low-dose ABCD AmBd for the treatment of candidemia in neutropenic patients and in liver transplant recipients are currently under way. therapy for nonmeningeal coccidioidomycosis was less than optimal [66] . Twenty-one patients received ABCD (1 Pooled data from emergency-use studies suggest the primary benefit of ABLC is as salvage therapy for fungal infections mg/[kgrd] for 2 weeks, followed by 2 mg/kg thrice weekly for 10 weeks). The relapse or failure rate was 58% at followrefractory to conventional AmBd. While IRAEs appear to be comparable for ABLC and AmBd, the decreased nephrotoxic up (mean, 9 weeks). In the treatment of candidemia, the mean daily dose employed potential of ABLC allows it to be used in patients with nephrotoxicity secondary to AmBd treatment. Elevations in serum in one open-label study was 3.9 mg/kg [64] . At present, the product packaging recommends an initial daily dose of 3.0-4.0 bilirubin and alkaline phosphatase levels are other notable laboratory abnormalities that may require close monitoring in pamg/kg, which may be increased to 6.0 mg/kg if there is no improvement or if there is evidence of progressive fungal disease. tients receiving prolonged therapy.
In light of the lower overall response rate with invasive aspergillosis, it may be prudent to initiate treatment with the maximum Amphotericin B Colloidal Dispersion daily dose of 6.0 mg/kg for all probable or proven cases of aspergillosis, until more dose-outcome data are available. One year following the introduction of ABLC in the United States, the FDA granted approval for the marketing of a second Efficacy -comparative trials. Two studies have been performed comparing ABCD and AmBd for the treatment of invalipid-based formulation of AmB, amphotericin B colloidal dispersion. ABCD is approved for the treatment of invasive aspersive aspergillosis [33] and for empirical treatment of febrile neutropenia [65] , respectively. However, only the latter study gillosis in patients who are either intolerant of or refractory to conventional AmBd. A recent supplemental new drug applicawas prospectively designed. Results of the study are available only in abstract format [65] . tion for empirical therapy in febrile neutropenia, based on double-blinded comparison with AmBd, did not receive FDA ap-
The efficacy and safety of ABCD in the treatment of invasive aspergillosis were compared with those of AmBd in a retroproval because of insufficient efficacy data.
The majority of ABCD recipients have been either intolerant spective, concurrent-control study [33] . All patients with proven or probable disease receiving treatment with either of or refractory to conventional AmBd therapy. To date, one comparative retrospective study [33] , seven noncomparative ABCD or AmBd were included in the study. Patients with AIDS or concomitant fungal infection were excluded. The open label studies, and case reports have been published in the literature [31, 32, 59 -63] . In addition, one large open-label number of evaluable patients (who received at least 7 days of therapy) in each group was 82 (ABCD) and 261 (AmBd). study of candidemia and one comparative trial evaluating ABCD vs. AmBd have been reported in abstract format Treatment response, survival at 120 days, and safety were assessed. To assess the potential impact of prior AmBd therapy [64, 65] .
Efficacy -open-label use. Overall, data on the efficacy and on the ABCD treatment group, a secondary post-hoc analysis was performed for each study endpoint by equalizing the two safety of ABCD in ú500 treated patients are available from case reports, open-label use, and randomized studies [30 -32, treatment groups for prior AmBd exposure.
Daily dosages administered were highly variable within each ized in a double-blind fashion to receive either ABCD (4 mg/kg) or AmBd (0.8 mg/kg) at least 72 hours after starting study group: 0.5 -8.0 mg/kg (ABCD) vs. 0.1 -1.4 mg/kg (AmBd). The median duration of treatment was similar beto receive empirical antibiotic therapy for neutropenic fever. A total of 101 patients received ABCD, while 93 received tween study groups (23.5 days and 22 days), with cumulative doses of 5.92 g and 1.06 g for ABCD and AmBd recipients, AmBd.
Because of the design of the study, a comparison of the respectively. A comparison of the baseline patient characteristics between study groups revealed significant differences:
relative efficacy of each formulation in treating documented infections is not possible. However, both treatments were more AmBd recipients were neutropenic (£500/mm 3 ) (42.5% vs. 15.9%), while more ABCD recipients had renal dysfunction equally successful, as defined by survival at 7 days after initiation of study drug, febrile state at end of study, evidence of (serum creatinine, §2 mg/dL) (40.7% vs. 8.7%). The overall clinical response rate was significantly higher for ABCDfungal infection, and termination of study drug because of toxicity. In general, one-third to more than half of the patients treated patients (48.8% [40 of 82] vs. 23.4% [61 of 261]; P õ .001). Notably, twice as many AmBd recipients than responded sufficiently; higher response rates were observed among patients not receiving either cyclosporine or tacrolimus ABCD recipients remained persistently neutropenic (49% vs. 27%) during the study, potentially negatively affecting treatconcurrently. Toxicity. IRAEs, including fever, chills, and hypotension, ment response in the AmBd group.
In addition, because the diagnosis of aspergillosis was made occur commonly with ABCD. The incidence and severity of IRAEs correlate with dosage as well as infusion time. In the postmortem for 17.2% of the AmBd recipients vs. none of the ABCD patients, treatment response may have been influenced phase I dose-escalation study, three of five patients who received ABCD at the maximum dosage of 8 mg/(kgrd) experiby the AmBd dosage selected on the basis of diagnosis. Subgroup analysis of patients whose diagnoses were made before enced fever, chills, rigors, and hypotension requiring vasopressors [32] . Most reactions occurred with the first and second or within the first 7 days of treatment revealed similar response rates between regimens. Further subgroup analysis revealed doses and usually were controlled with premedications or subsided with subsequent dosing. that initial treatment with AmBd did not alter response rates between groups.
Pooled data from noncomparative studies indicate that more than one-third of ABCD-treated patients reported either chills Mortality rates among patients with aspergillosis were 50% and 66.1% for ABCD and AmBd, respectively. Cause of death or chills and fever. Up to 86% of patients have experienced IRAEs in different studies using different dosages. Published was not stated. More AmBd-treated patients developed renal toxicity during treatment than did ABCD recipients (43.5% vs.
data from comparative studies thus far have not addressed the relative occurrence of IRAEs with ABCD vs. AmBd [33, 65] . 8.2%). The median time to renal toxicity for AmBd recipients was estimated to be 27 days (Kaplan-Meier analysis); similar However, data presented recently to the FDA for supplemental new-drug-application consideration indicate that infusion-reestimation was not performed for the ABCD recipients because too few had renal toxicity.
lated toxicities (such as fever, chills, hypotension, and hypoxia) occurred more frequently in the ABCD recipients than in According to the authors, IRAEs could not be adequately assessed because of the retrospective design of the study. Other AmBd recipients. It is noteworthy that hypoxic events were usually associated with chills and fever; all were reversible and laboratory abnormalities included increases in alkaline phosphatase and serum bilirubin levels, without significant changes without sequelae. Nephrotoxicity occurred significantly less commonly with in hepatic transaminase levels. A lesser degree of change from baseline was observed for ABCD recipients than for AmBd ABCD than with AmBd in both comparative studies [33, 65] . In the double-blind randomized trial, ABCD therapy caused recipients.
While the overall response rate, mortality rate, and renal significantly less renal toxicity than did AmB in patients who did or did not also receive cyclosporine or tacrolimus. Renal safety appeared to favor ABCD, the authors cautioned that ''it is not appropriate to conclude that ABCD is superior to toxicity was defined as at least a 50% decline in creatinine clearance or a doubling of or an increase of 1.0 mg/dL in the amphotericin B as initial treatment of aspergillosis from results of a retrospective, unblinded study comparing different populaserum creatinine value. For adults not receiving concurrent nephrotoxic therapy, the incidence of nephrotoxicity with tions of patients.'' In addition, the estimated median time to nephrotoxicity (27 days) was delayed beyond the median dura-ABCD and AmB was 8.5% and 21%, respectively. In contrast, 21% vs. 67%, respectively, developed renal dysfunction when tion of treatment with AmBd (22 days), suggesting that most AmBd patients would have completed therapy before the develgiven concurrent cyclosporine or tacrolimus. One large open-label study of 168 patients showed that opment of nephrotoxicity.
Another comparative study evaluated ABCD vs. AmBd for 69% of patients with normal serum creatinine values at baseline still had normal values at the end of ABCD therapy [31] . the empirical treatment of febrile neutropenia [65] . Patients were separated into four groups, comprising adults with or
The median cumulative dose and treatment duration were 2,388 mg and 12.5 days, respectively. In the phase I dosewithout concurrent cyclosporine or tacrolimus therapy and children in similar subgroups. Patients in each group were randomescalation study, which excluded patients with a baseline se-rum creatinine level of ú2.0 mg/dL, a doubling of or ú50% Published data include 4 open-label compassionate-use studies, 7 case reports, 1 open-label noncomparative study of HIV/ increase in the serum creatinine level (up to 2.5 mg/dL) occurred in 17% of patients [32] . Although the cumulative dose patients with cryptococcal meningitis, and 1 report on the data from two comparative studies in febrile neutropenic adult and and treatment duration for those patients were not stated in the study, the authors did not note any relationship between pediatric patients [34 -39, 67 -75] . More recently, three comparative studies have been presented as abstracts at professional the total ABCD dose and serum creatinine value. It is unclear whether the daily dose administered affects the onset and meetings; one study compared L-AmB with AmBd for the treatment of cryptococcal meningitis [76] , while the other comdegree of nephrotoxicity.
Summary -ABCD. In comparison with ABLC, ABCD has pared high-dose vs. low-dose L-AmB for the treatment of invasive aspergillosis [77] . been less studied in fungal infections other than candidiasis or aspergillosis. As an example, few HIV-positive patients with
The third abstract presented results from a large prospective, double-blind, randomized trial evaluating the efficacy and cryptococcal meningitis have been treated with ABCD, even though ABCD appeared to be most efficacious in a murine safety of L-AmB vs. AmBd for the empirical treatment of febrile neutropenia in 687 patients [78] . Results of the study model of cryptococcosis comparing the three lipid-based products [27] . Similar to the finding for ABLC, subgroup analysis of were also presented to the FDA Antiviral Advisory Committee on 16 July 1997 as pivotal phase III data supporting the new those patients whose AmBd treatment for invasive aspergillosis failed suggests that ABCD has a potential role as salvage therdrug application of AmBisome. In addition to the above studies, L-AmB has been prospectively evaluated as antifungal prophyapy. However, variable dosing for ABCD makes the optimal treatment dose uncertain for most infections, with the possible laxis in two randomized, penia. Documented infections in L-AmB patients were due most commonly to Aspergillus species, followed by Candida pares ABCD to fluconazole (400 mg/d) for neutropenia following bone marrow transplantation or chemotherapy.
species. The overall response rates were 60% and 74% for aspergillosis and candidiasis, respectively. Similar to ABCD, On the basis of comparative data with AmBd, the incidence of IRAEs (e.g., fever and chills) associated with ABCD may varying dosages were used in the various studies, averaging 3 mg/(kgrd). be higher than with ABLC. The recommended infusion time for ABCD is also 2.5 times longer than with ABLC. Similar Efficacy -comparative trials. One study prospectively compared L-AmB with AmBd in the treatment of cryptococcal to ABLC, ABCD has been demonstrated to be less nephrotoxic than AmBd. However, accurate assessment of the relative meningitis in HIV-positive patients [76] . A total of 28 patients were randomized to receive either L-AmB (4 mg/kg; n Å 15) nephrotoxicity between the two lipid formulations requires direct comparison between ABLC and ABCD. In addition, both or AmBd (0.7 mg/kg; n Å 13) daily for 3 weeks, followed by fluconazole (400 mg/d) for 7 weeks. The study groups were formulations have demonstrated hepatotoxic potential consisting of an elevation in alkaline phosphatase and serum bilirusimilar with respect to lumbar opening pressure and CSF cryptococcal antigen titers, while more patients in the L-AmB group bin levels, without significant change in hepatic transaminase levels.
had altered mental status at enrollment in the study. The primary study endpoint was time to CSF sterilization, and time to clinical response was the secondary objective. The AmBisome median time to sterilization of the CSF was shorter with L-AmB than with AmBd therapy (14 days vs. ú21 days). AmBisome (L-AmB) has been licensed for use in Europe for ú5 years but only recently became available commercially When the study groups were compared on day 14 of therapy, a significantly greater number of L-AmB patients had CSF in the United States. AmBisome received FDA approval in August 1997 for the treatment of patients with aspergillar, culture conversion (67% vs. 11%). However, the time to clinical response (median, 15 days) as well as the clinical failure candidal, and/or cryptococcal infections refractory to AmBd or in patients intolerant of AmBd. An additional approved indicarate (23%) during initial therapy did not differ between groups. None of the L-AmB vs. two AmBd recipients discontinued tion is for the empirical treatment of febrile neutropenia.
In comparison with use of ABLC and ABCD, the use of therapy because of toxicity. This lack of toxicity and the earlier mycologic response with L-AmB suggest a potential role of AmBisome has been evaluated in a greater number of patients.
L-AmB in the treatment of cryptococcal meningitis. The overall
Response to treatment was observed in 49 patients (49%) in the AmBd arm, 68 (58%) in the LD L-AmB arm, and 75 (64%) clinical response rate and the time of CSF culture conversion noted in this comparative study for L-AmB are similar to the in the HD L-AmB arm; however, statistical significance was noted only for the HD L-AmB group in comparison with findings of a noncomparative open-label study [37] .
High-dose (HD) vs. low-dose (LD) L-AmB treatment of AmBd. As expected, the median time to response (7, 8, and 10 days) appeared to correspond closely to the median time of invasive aspergillosis has been studied in neutropenic cancer patients [77] . Surprisingly, the clinical and radiological responses slightly 2 developed pulmonary aspergillosis 2 weeks after the study drug was discontinued (1 in each of the L-AmB arms). Definifavored the LD group (68% vs. 49% and 63% vs. 54%, respectively). However, overall survival and mortality rates due to tions for proven or presumed fungal infections were not clearly stated. In addition, the outcomes for those patients were not invasive aspergillosis were similar in both groups. Given the small number of documented infections, it is difficult to assess stated. The remainder of the patients whose treatment failed had unresolved fever at the end of the study. the benefit of LD therapy. In addition, an accurate assessment of the treatment response is problematic since patients who Given that antiviral as well as nonsystemic antifungal therapies were used at the discretion of the treating physician, the had received L-AmB treatment for only 1 day were included in the interim study analysis. More conclusive results await relative efficacy of empirical treatment in those without proven fungal diseases is difficult to assess. In addition, survival at final data analysis.
One published report presented the combined results from 30 days was not different among study groups ( §87%). It is interesting that both cases of proven pulmonary aspergillosis two prospective randomized multicenter European trials comparing L-AmB with AmBd for the empirical treatment of fedeveloped in the L-AmB treatment arms, with none observed in the AmBd group. Significantly more AmBd patients experibrile neutropenia [75] . Both studies compared AmBd at a dosage of 1 mg/(kgrd) vs. L-AmB at dosages of 1 mg/(kgrd) enced side effects than did those receiving LD L-AmB or HD L-AmB (64% [65 of 102] vs. 36% [42 of 118] and 43% [51 (LD) and 3 mg/(kgrd) (HD). Patients were enrolled in the study if they were neutropenic (õ0.5 1 10 9 neutrophils/L) and of 118]; P õ .01).
The most frequently reported side effects were first-doseremained febrile with a temperature of §38ЊC for 96 hours despite broad-spectrum antibacterial therapy. related fever and rigors, hypokalemia, and nephrotoxicity. Allergic reactions, including rash, flushing, bronchospasm, facial A total of 134 adult patients and 204 pediatric patients were enrolled in the two studies; 102 patients were randomly assigned edema, rigors, and back pain, occurred with 2% of administered AmBd doses, followed by 0.8% of HD L-AmB and 0.6% of to receive AmBd, while 118 received LD L-AmB and 118 received HD L-AmB. Most patients had underlying hematologic LD L-AmB doses. Nephrotoxicity, as defined by a 100% or more increase in baseline serum creatinine, occurred signifimalignancies. Antifungal prophylaxis with itraconazole, fluconazole, and/or an oral polyene was permitted until the day of cantly more in the AmBd than the LD and HD L-AmB arms (24% vs. 10% and 12%; P õ .01). Subgroup analysis of 81 enrollment. Administration of nonsystemic antifungals was continued for nearly half of the patients in each treatment group.
patients who did not receive other concomitant nephrotoxic medication indicated a much lower incidence of nephrotoxicity Antiviral therapy was prescribed at the discretion of the treating physician to at least one-third of the patients in each group. Safety (zero to 3%) in the L-AmB arms, while the incidence remained unchanged for patients receiving AmBd. was the primary study endpoint. Efficacy was the secondary endpoint, assessed by response and failure rates.
Serum creatinine levels stabilized or reversed in those patients who switched from AmBd to L-AmB secondary to renal Response was defined by a minimum of 3 consecutive days without fever (temperature of õ38ЊC), with accompanying neutoxicity. Liver function abnormalities, specifically in alkaline phosphatase, serum bilirubin, and transaminase levels, were trophil recovery to 0.5 1 10 9 /L. Failure was defined by any one of the following: addition of another systemically active antifungal not different between treatment arms. In light of the small total number (6 of 335; 1.7%) and the lack of demonstrable medication, development of a systemic fungal infection, or unresolved fever at study end. Treatment ended with the resolution difference in fungal infections among treatment arms, the reversibility of AmBd-induced nephrotoxicity, and similar surof fever, recovery of neutrophils to §0.5 1 10 9 /L for 3 consecutive days, death, unresolved toxicity, or request (from patient or vival rates, future studies will need to address the cost-benefit ratio of using liposomal product for the empirical treatment of physician) for withdrawal from the study. A total of 335 patients (202 children and 133 adults) were evaluable for efficacy.
febrile neutropenia in this patient population.
A larger prospective, multicenter trial comparing L-AmB sion. Nephrotoxicity was defined as a doubling of the serum creatinine value at baseline for adults, provided that the peak with AmBd for empirical treatment of febrile neutropenia was recently completed in the United States [78] . Results from this serum creatinine concentration was ú1.2 mg/dL. The incidence of nephrotoxicity was significantly less in patients receiving trial are available in abstract only but were presented to the FDA Antiviral Advisory Committee on 16 July 1997 as pivotal L-AmB than in AmBd recipients (19% [64 of 343] vs. 34% [116 of 344]; P õ .001). Of note, the mean peak serum creatiphase III data supporting the new drug application of AmBisome. Data presented in the abstract, at the FDA hearing in nine value was 1.24 mg/dL and 1.52 mg/dL for L-AmB and AmBd, respectively. No difference in the frequency of hepatoJuly, and in the package insert serve as the basis for the discussions below [86, 87] .
toxicity was noted between study groups. On the basis of the above study results, L-AmB was considInclusion criteria for study patients were the following: an age of 2 -80 years, absolute neutrophil count of õ500, and ered equivalent to AmBd for the empirical treatment of febrile neutropenia. For proven emergent fungal infections, L-AmB fever for at least 96 hours despite broad-spectrum antibacterial therapy. A total of 687 patients were randomized to receive appears superior to AmBd; however, the short-term survival rate is not improved. Whether or not treatment with an expeneither L-AmB (n Å 343) or AmBd (n Å 344) in a double-blind fashion. Approximately one-third of the patients in each arm sive liposomal formulation results in a meaningful difference in long-term survival rates is unknown. Finally, while L-AmB were stratified into the high-risk category, which included patients who underwent allogeneic bone marrow transplantation, was shown to be less nephrotoxic than AmBd by study definition, the clinical significance of the difference in mean peak had relapsed acute leukemia, and had previously received empirical therapy with AmBd.
serum creatinine values between study groups is debatable. Toxicity. L-AmB appears to have a remarkably low rate The initial daily treatment dose was 3 mg/kg for L-AmB vs. 0.6 mg/kg for AmBd; daily dosages could be increased up to of IRAEs, compared with that reported for ABLC and ABCD; most studies reported an incidence rate of õ5% [34 -39, 67, 6 mg/kg and 1.2 mg/kg, respectively, according to protocol guidelines. Dosage reduction was allowed for toxicity, to 1. 5 73, 79 -82] . However, the incidence of fever, chills, and rigors associated with initial infusion was near 20%, compared with mg/(kgrd) for L-AmB and 0.3 mg/(kgrd) for AmBd. Empirical treatment was to continue until neutrophil recovery and up ú50% for AmBd in a large comparative trial of empirical treatment for febrile neutropenia [78] . In addition, the infusion to 3 days following recovery, for a maximum of 42 days. The treatment duration for confirmed infection was extended to 14 time used with L-AmB is shorter than that for ABLC and ABCD in most studies. With daily dosages of 0.5 mg/kg to 6 days after cultures returned to negative. The mean duration of treatment was Ç10 days for both groups. mg/kg, the drug usually has been infused over 30 -60 minutes, with no test dose administered prior to the first infusions. HowComposite success rate was the primary study endpoint, which had to include all of the following: survival at 7 days ever, on a few occasions, low-back pain during infusion has been reported, which improved or disappeared with an increase posttreatment, resolution of fever during neutropenia, resolution of mycologically confirmed study-enrollment fungal infecof the infusion time to 2 -3 hours [80 -82] . Of note, L-AmB was infused over 2 hours in the largest prospective comparative tions, absence of emergent fungal infection during or within 7 days posttreatment, and no premature discontinuation of drug trial performed to date, with an unexpectedly higher reported incidence of IRAEs [78] . secondary to toxicities. L-AmB and AmBd treatment resulted in equivalent composite success rates (50% and 49%).
Other rare events noted during infusions of L-AmB include confusion, headaches [79, 81, 82] , and dyspnea [81 -83] . The The secondary efficacy endpoint was the incidence of emergent fungal infections. The number of proven fungal latter pulmonary reaction appears to differ from those reported with AmBd in that dypsnea was not associated with bronchoinfections was lower in the L-AmB recipients than in AmBd recipients (11 [3.2%] vs. 27 [7.8%]); however, the total numspasm, fever, chills, or rigors [88, 89] . Anaphylaxis has also been reported in at least three cases in the literature, with ber of emergent fungal infections (proven and presumed) was the same in each group (n Å 43; 12.5%). Criteria for proven signs and symptoms consisting of vomiting, epigastric pain, abdominal tightness, bronchospasm, facial flushing, and infections were defined according to the Mycoses Study Group grading system; however, criteria for presumptive disweating [84, 85] . The onset of reaction was within seconds of the start of infusion and resolved within 4 hours after the agnosis were not specified. Candidemia and invasive pulmonary aspergillosis accounted for the majority of proven infecinfusion was discontinued. A test dose prior to initial infusion was not called for in the product packaging, despite the latter tions, while the majority of presumed infections were pulmonary. Survival at 7 days posttreatment was similar bereaction. Similar to findings with ABLC and ABCD, nephrotoxicity tween groups (93%, L-AmB; 90%, AmBd); long-term survival rates were not determined. associated with L-AmB therapy appears to be significantly less than with conventional AmBd therapy. Overall, the reported A significantly lower incidence of IRAEs such as fever, chills/rigors, and cardiorespiratory events was noted on study incidence of nephrotoxicity, depending upon definition and dosage used, ranges from zero to 31%. When L-AmB was day 1 among L-AmB recipients. Study drugs were administered over 2 hours, with no premedication given prior to initial infugiven at 1 mg/(kgrd) for the empirical treatment of febrile neutropenia, none of the patients who did not receive concomithese abnormalities may occur in up to 26% of patients treated, all appear to be reversible. Drug is discontinued only on rare tant nephrotoxic drugs experienced nephrotoxicity [75] . Furthermore, safety data from a phase II/III clinical trial indicate occasions; no cases of fatal hepatitis have been reported. that 85% of the 71 L-AmB recipients who had normal serum creatinine values at the start of therapy still had normal values
Comparison of ABLC, ABCD, and L-AmB at the end of treatment. Eleven of those patients received cumulative doses exceeding 5 g. Although no apparent difference All three lipid-based AmB products differ in the type of phospholipid and the phospholipid:AmB ratio, which may be in the incidence of nephrotoxicity was noted between LD and HD L-AmB therapy in the previous two large comparative important determinants of fungicidal activity and toxicity [20] . Dosage equivalency among the three products has not been studies, another investigator observed a significantly greater incidence in patients receiving 4 mg/(kgrd) vs. 1 mg/(kgrd) established. Adding to the uncertainty are the variable dosages used in clinical trials within and among different products. of L-AmB (44% vs. 9%) [77] . As a result, the daily dose of L-AmB is expected to be an important factor associated with Pharmacokinetic properties in terms of plasma and tissue levels also differ among the products. However, the clinical signifithe risk of nephrotoxicity.
Other toxicities associated with L-AmB therapy that were cance of such differences has not been addressed. Overall, treatment with all three lipid-based AmB prodalso reported with the other lipid-based products are abnormalities in hepatic function, manifested by elevation of the alkaline ucts has been evaluated for candidiasis, aspergillosis, cryptococcosis, coccidioidomycosis, mucormycosis, and fusarphosphatase level and conjugated bilirubin. Unlike with the other two products, transaminase values were also noted to iosis, in descending order of frequency. Published data on ABLC and ABCD are derived primarily from compassionincrease with L-AmB treatment. A retrospective report on the use of L-AmB as salvage therapy in 133 episodes of infection ate-use studies of patients refractory to or intolerant of conventional AmBd therapy, while the use of L-AmB has been found hepatic dysfunction possibly attributable to L-AmB in 17% of the episodes; two cases were severe enough to require largely as empirical therapy for febrile neutropenia. When used at five times the AmBd dose for empirical treatment of discontinuation of therapy, with subsequent resolution of abnormalities. The maximum peak levels of aspartate transamifebrile neutropenia, L-AmB reduced the number of proven emergent fungal infections, yet the short-term survival rate nase, alkaline phosphatase, and bilirubin were 510 IU/L, 1,362 IU/L, and 310 mmol/L, respectively [36] . In another large sewas not altered [78] . For the treatment of proven infections, the response rates, ries of patients described by Ringden et al., 26% of 197 treatment episodes were associated with an increase in alkaline in general, are lower for aspergillosis than for candidiasis; however, the results of open-label trials indicate that the rate phosphatase level; the abnormalities were observed primarily in liver transplant recipients [81] .
of clinical cure with use of L-AmB is greater than that reported with ABLC and ABCD. In addition, both ABLC and L-AmB Summary-L-AmB. L-AmB is the most studied of any lipidbased AmB product. However, efficacy data regarding proven have been compared prospectively with AmBd for the treatment of cryptococcal meningitis in a small number of HIVsystemic fungal infections are limited; empirical therapy for febrile neutropenia has been the primary indication. The dosage studied positive patients. Neither lipid product resulted in a better clinical response than with AmBd when used at a daily dosage 3 -varies by indication: 1 mg/kg for prophylactic therapy, 1-6 mg/ kg for empirical therapy, 3 mg/kg for cryptococcal meningitis, 5 times greater than the dosage of AmBd. In fact, a higher number of patients receiving ABLC had persistently positive and up to 5 mg/kg for aspergillosis. L-AmB treatment resulted in earlier CSF sterilization but similar clinical response and failure CSF cultures at the end of treatment; in contrast, CSF sterilization occurred significantly sooner with L-AmB than with conrates when compared with AmBd prospectively in the treatment of cryptococcal meningitis in HIV-positive patients.
ventional AmBd therapy. The difference in mycologic response to ABLC and LDespite a much faster infusion rate (30 -60 minutes) used in most studies, L-AmB has been associated with the lowest AmB must be confirmed with a larger number of patients. To date, few HIV-positive patients with cryptococcal meningitis incidence of IRAEs among the lipid-based products. However, occasionally, the infusion time may need to be extended to 2 -have been treated with ABCD. Furthermore, ABLC has also been compared prospectively with AmBd for the treatment 3 hours for patients who complain of low-back pain related to the infusion. More important, dyspnea and anaphylaxis necessiof invasive candidiasis. No improvement in efficacy was seen with ABLC when given at five times the AmBd daily dose tating discontinuation of therapy rarely have been reported. LAmB is less nephrotoxic than AmBd when given at doses for the treatment of candidemia. No comparative trial report has been published to date evaluating ABCD vs. AmBd prothree times that of AmBd in adult and pediatric patients. Renal function remains normal at the end of L-AmB treatment in a spectively for the treatment of documented infections; one recently completed randomized study that compared ABCD majority of patients whose serum creatinine level is normal at the start of therapy. However, no clinical trial data are available at this point directly comparing the efficacy and safety of ABLC, ABCD, mended dosing (3 mg/kg up to 6 mg/kg), the daily cost of drug ranges between $330 and $660 for the same patient. and L-AmB.
Given the paucity of efficacy data from controlled and comWhile the drug-acquisition costs for the lipid products are exceedingly high, when performing cost-effectiveness analysis parative trials, several important issues concerning the available efficacy results deserve comment. Definitions for ''evaluable'' one needs to balance the acquisition cost with (1) the costs associated with the failure to prevent fungal infections, in cases patients as well as treatment response are not provided routinely, which may impact on the comparison of response rates of empirical treatment, (2) the cost of nephrotoxicity, and (3) the cost of premedications used to minimize IRAEs. among studies. In addition, response rates were not consistently reported with proven vs. suspected fungal infections. FurtherEfficacy evaluations of these products have focused primarily on candidiasis and aspergillosis. Limited data from one prospecmore, dosages used with ABCD and L-AmB have been variable among studies. Critical factors such as cumulative dose or tive controlled trial on candidemia indicated that when used at five times the AmBd dose, ABLC was not more efficacious. In duration and presence of neutropenia also were inconsistently reported. In those studies that stratified treatment response with contrast, ABCD appeared to be more efficacious than AmBd in a retrospective concurrent-control study of aspergillosis. However, neutropenia, higher rates of treatment failure were observed with all three lipid products in patients who were persistently more AmBd recipients remained persistently neutropenic during the study, potentially influencing treatment response. In addition, neutropenic throughout the treatment course. Finally, mycologic follow-up was not performed in most studies to document when patients receiving AmBd who had postmortem-diagnosed aspergillosis were excluded, the difference in response rates did eradication of the organisms.
While treatment with each of the three products resulted in not reach statistical significance. Thus, neither ABLC nor ABCD demonstrated superior efficacy when directly compared with lower risk of nephrotoxicity when given at daily dosages up to five times that of conventional AmBd, it is unknown whether AmBd. However, they appear to have a potential role in salvage therapy for those cases refractory to treatment, defined by receipt one lipid product is superior in this regard. It does appear that acute IRAEs occurred less frequently in L-AmB-treated of at least 500 mg of AmBd. Accordingly, none of the lipid-based products should be patients than in those receiving ABLC, ABCD, or conventional AmBd. Of note, only ABCD requires a test dose prior to initial considered as first-line therapy for documented invasive mycoses. Relatively less expensive and nonnephrotoxic alternative therapy, according to the product packaging. L-AmB has been infused as fast as 30 -60 minutes, more rapidly than ABLC therapies should be considered when appropriate. For example, fluconazole should be considered for the treatment of uncom-(2.5 mg/[kgrh]) and ABCD (1 mg/[kgrh]), which is an attractive feature for ambulatory home infusion therapy. Close moniplicated candidemia due to C. albicans and in maintenance therapy for cryptococcal meningitis in HIV-positive patients. toring of both hepatic and renal function during treatment with all three products seems prudent at this point because of the Fluconazole therapy given orally in cases in which absorption is adequate further enhances this drug as a cost-effective therapotential for liver function abnormalities.
Given the heterogeneity of the patient populations and the peutic option. An additional indication for antifungal therapy is empirical varying indications, dosages, and treatment durations, comparison between products is difficult. Thus, until direct comparative treatment in neutropenic patients unresponsive to antibacterial therapy. As demonstrated in the largest prospective, randomstudies are performed with respect to clinical efficacy and toxicities, each lipid-formulated AmB product must be evaluated ized, comparative study involving L-AmB and AmBd, the total number of emergent fungal infections (proven and presumed) separately.
was small, and these occurred at the same rate (12.5%); however, there were fewer proven infections in the L-AmB arm,
Costs and Role of Therapy with no effect on the short-term survival rate [78] . On the basis of the study results, the additional direct treatment Allocation of limited health care dollars to the use of such high-acquisition-cost lipid-based agents can be considered only cost associated with the use of L-AmB to reduce the incidence of invasive fungal infections by Ç5% was in excess of $2.6 if they prove to have superior efficacy and reduced toxicities in comparison with conventional AmBd or other effective thermillion. A recent meta-analysis of 24 randomized controlled trials with 2,758 neutropenic cancer patients receiving prophylactic or apeutic options. According to the average wholesale price dated December 1997, the drug-acquisition cost is the highest for Lempirical antifungal therapy revealed a lack of survival benefit, despite significant reduction in the incidence of invasive fungal AmB, followed by ABLC and then ABCD, all of which are significantly more costly than conventional AmBd. The daily infection [90] . In the current setting of limited health care resources, better predictors to identify those neutropenic patients at drug-treatment cost for a 70-kg adult patient given L-AmB at a dose of 5 mg/kg vs. AmBd at a dose of 1 mg/kg, on the basis highest risk for the development of invasive fungal infections are urgently needed. In addition, future studies should perform costof the average wholesale price, is $1,300 and $24, respectively. Comparatively, therapy with ABLC for the same patient at 5 benefit analyses that include data on length of hospital stay and long-term survival rates in order to aid clinicians in making the mg/(kgrd) costs $570. Depending on the dosage used, the daily cost for ABCD varies. Based on the manufacturer's recommost cost-effective therapeutic decision.
